[HTML][HTML] The cost-effectiveness of a COVID-19 vaccine in a Danish context
K Debrabant, L Grønbæk, C Kronborg - Clinical Drug Investigation, 2021 - Springer
Abstract Background and Objectives Covid-19 vaccines approved by the EU, UK and USA
have been found to be safe and effective. The cost effectiveness of these vaccines depends …
have been found to be safe and effective. The cost effectiveness of these vaccines depends …
[HTML][HTML] Cost-effectiveness analysis of COVID-19 vaccination in Poland
K Orlewska, W Wierzba… - Archives of medical …, 2022 - ncbi.nlm.nih.gov
Results In the base case analysis the incremental cost per QALY gained associated with
vaccinating the whole population is 6249 PLN. For individuals aged 60–69 years and> 80 …
vaccinating the whole population is 6249 PLN. For individuals aged 60–69 years and> 80 …
Pharmaco economics analysis of COVID-19 vaccines in Ukraine
TY Volodymyrovych, SV Ivanovich… - Journal of …, 2021 - journal.article2publish.com
Aims: To evaluate pharmacoeconomics for the vaccination of COVID-19 vaccine and
analyze the cost-effectiveness for the vaccine in Ukraine. Study design: we have analyzed …
analyze the cost-effectiveness for the vaccine in Ukraine. Study design: we have analyzed …
[HTML][HTML] Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic
Y Wang, N Luangasanatip, W Pan–ngum… - The European Journal of …, 2023 - Springer
Objective This study aimed to assess the cost-effectiveness of COVID-19 vaccines, preferred
COVID-19 vaccine profiles, and the preferred vaccination strategies in Thailand. Methods An …
COVID-19 vaccine profiles, and the preferred vaccination strategies in Thailand. Methods An …
[HTML][HTML] A cost–benefit analysis of COVID-19 vaccination in Catalonia
(1) Background: In epidemiological terms, it has been possible to calculate the savings in
health resources and the reduction in the health effects of COVID vaccines. Conducting an …
health resources and the reduction in the health effects of COVID vaccines. Conducting an …
Racing against COVID-19: a vaccines strategy for Europe
R Veugelers, G Zachmann - 2020 - econstor.eu
The fast development of vaccines is an essential part of the long-term solution to COVID-19,
but vaccine development has high costs and carries the risk of high failure rates. There are …
but vaccine development has high costs and carries the risk of high failure rates. There are …
[HTML][HTML] How should a safe and effective COVID-19 vaccine be allocated? Health economists need to be ready to take the baton
Recently, there have been encouraging commitments around the world to manufacture
coronavirus disease 2019 (COVID-19) vaccines in anticipation of results from clinical …
coronavirus disease 2019 (COVID-19) vaccines in anticipation of results from clinical …
[HTML][HTML] Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region: a mathematical modelling study
Y Liu, FG Sandmann, RC Barnard… - The Lancet Regional …, 2022 - thelancet.com
Summary Background Countries in the World Health Organization (WHO) European Region
differ in terms of the COVID-19 vaccine supply conditions. We evaluated the health and …
differ in terms of the COVID-19 vaccine supply conditions. We evaluated the health and …
[HTML][HTML] The impact of COVID-19 vaccination on the Italian healthcare system: a scenario analysis
A Marcellusi, G Fabiano, P Sciattella… - Clinical Drug …, 2022 - Springer
Abstract Background and Objective During 2020, the only instruments for fighting against the
pandemic peaks were lockdowns, physical distancing, closure of schools and non-essential …
pandemic peaks were lockdowns, physical distancing, closure of schools and non-essential …
[HTML][HTML] Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people
Background: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 (Oxford-AstraZeneca)
COVID-19 vaccines have demonstrated high efficacy against infection in phase 3 clinical …
COVID-19 vaccines have demonstrated high efficacy against infection in phase 3 clinical …